Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility of a New Technology for Isolating Circulating Tumour Cells in Selected Cancer Patients and Healthy Volunteers

NCT03979339 is registered in ClinicalTrials.gov with Centre Oscar Lambret as lead sponsor.

NCT NCT03979339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03979339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility of a New Technology for Isolating Circulating Tumour Cells in Selected Cancer Patients and Healthy Volunteers
Lead sponsor
Centre Oscar Lambret
Phase
Not applicable
Overall status
Unknown status
Start date
March 11, 2020
Completion date
December 31, 2023
Enrollment
76 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

circulating tumor cell, her2-positive metastatic breast cancer, hormone-resistant prostate cancer, ovarian cancer